---
run_id: halo-evidence-vs-diagnosis-validation-v7-vanilla-02
created: 2026-05-23
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
model_condition: vanilla
run_number: 2
model_name: gemma4:31b
model_id: gemma4:31b
model_snapshot: Ollama model ID 6316f0629137
runtime: Ollama local HTTP server; version 0.24.0
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 32768
seed: 201
prompt_source: condition packet (vanilla) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 5a42e17859b4a23ae36d2682474f8d0369ffc492c200375fd79a14bf3b322262
source_packet: the frozen Advisor prompt alone, with no added material - see run-packet.md
source_packet_sha256: 5a42e17859b4a23ae36d2682474f8d0369ffc492c200375fd79a14bf3b322262
condition_packet_sha256: 5a42e17859b4a23ae36d2682474f8d0369ffc492c200375fd79a14bf3b322262
output_file: model-outputs/vanilla-02.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - vanilla (run 02)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v7-v1`, condition `vanilla`, run 2 of 8. Real local-model run: `gemma4:31b` via Ollama, seed 201, on the frozen condition packet.

## Output

**Recommendation: Run the targeted evidence pass.**

**Why:**
Your current growth is a "mirage" created by financial engineering and selection bias, not product-market fit. 72% of your expansion revenue is tied to short-term discounts, meaning you haven't increased the value of the product; you've simply pulled forward renewals by discounting. More critically, the 31% retention rate among front-line reviewers is a catastrophic signal. In B2B workflow software, if the end-user (the reviewer) abandons the tool, the "champion" (the ops lead) cannot sustain the account long-term.

Scaling now (Option 1) would be "scaling a leak"—you would be hiring implementation teams to deploy a feature that front-line users are already rejecting. Narrowing to regulated insurance (Option 3) is premature because you haven't yet determined if the failure in that segment is a fundamental "explainability" flaw or a symptom of the same poor front-line adoption seen across all segments. You must decouple the *financial* success (discounts/renewals) from the *functional* success (user adoption) before committing next year's budget.

**The strongest reason against this:**
It creates a "momentum gap" and risks political friction with Sales and the Board. You are essentially asking the CEO to temper an "upbeat story" and pause the revenue engine (discounts) twelve days before the budget is locked. In a high-pressure environment, this can be perceived as "analysis paralysis" or a lack of confidence, potentially damaging your standing with a leadership team that currently feels they have finally "found the wedge."

**The observable evidence that would change my mind:**
I would pivot to the "Scale Broadly" option only if you can demonstrate that the 31% front-line retention rate is a "cold start" problem rather than a value problem. Specifically, if you find a cohort of users who—despite not receiving the strategic-feature pitch or a discount—have an organic retention rate of >60% over four weeks, it would prove the product has intrinsic value that is simply being masked by poor onboarding. Until that number moves, the revenue bump is a lagging indicator of a sales tactic, not a leading indicator of product success.
